News

Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics,…

2 years ago

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that…

2 years ago

GeneDx Announces Reverse Stock Split

STAMFORD, Conn., April 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic…

2 years ago

Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary…

2 years ago

Vistant Named by Financial Times as One of the Americas’ Fastest-Growing Companies Once Again

Vistant Remains in the Top 25 Percent Out of 500 CompaniesTOWSON, Md., April 27, 2023 (GLOBE NEWSWIRE) -- Vistant, a…

2 years ago

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation…

2 years ago

Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty…

2 years ago

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease

On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-endCAMBRIDGE, Mass., April…

2 years ago

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

-Capricor’s StealthX™ Exosome Platform Designed to Support the Advancement of Next Generation Vaccines and Therapeutics-SAN DIEGO, Calif., April 27, 2023 (GLOBE…

2 years ago